It's melanoma.
Now what?
Know your risk. Navigate your melanoma journey in confidence with the DecisionDx-Melanoma test.
Know your risk. Navigate your melanoma journey in confidence with the DecisionDx-Melanoma test.
A melanoma diagnosis can feel overhelming, and you may have questions about what comes next. That is where the DecisionDx-Melanoma test comes in sThis genomic test provides information about your individual risk to support melanoma care decisions for patients with stage I-III cutaneous melanoma. By analyzing a small sample from your original biopsy, it evaluates your tumor’s biology to help you and your healthcare provider create a risk-aligned care plan, giving you more confidence as you move forward.
Represents the only melanoma genomic test shown to be associated with improved patient survival1
Uses your tumor biology to deliver personalized insights to help guide more precise care
Offers coverage through Medicare and many private insurers, with an market-leading financial assistance program.
By better understanding the risk of your individual tumor biology, your provider can make better management decisions. The bottom line? More personalized treatment leads to better outcomes.
Not all GEP tests are the same. DecisionDx-Melanoma is the only test that can provide you with a comprehensive test result that gives you a clinically validated, personalized risk assessment. DecisionDx-Melanoma is the only test with over 200,000 patients studied and 50 peer-reviewed publications
The value of a test is driven by the value of information it provides. DecisionDx-Melanoma has continued to show that it offers data that is above and beyond what traditional staging can provide.
The fourth component is a group of nine housekeeping genes whose measurement allows normalization of the RNA expression for analysis.
Wherever you are in your melanoma journey, you deserve clarity. Ask your provider about DecisionDx-Melanoma and take the next step toward informed, confident care.